Industry Expansion and Market Dynamics
The Korean medical aesthetics industry is entering a new phase, marked by significant growth and transformation. Major players, such as PharmaResearch, Hugel, and Classys, have posted record profits and are accelerating their global expansion. However, behind the rapid growth, the industry is also experiencing growing pains, including rumors of management rights’ sell-off, leadership changes, and business structure reorganization.
In addition to large corporations, Korean companies specializing in Korean medical aesthetic supplies are gaining global recognition. Businesses like “To The Beauty” are dedicated to empowering beauty professionals by providing access to premium skincare products, botox, fillers, and other medical aesthetic solutions. By offering cutting-edge Korean cosmetology innovations, they help dermatologists and clinicians elevate their practice with advanced rejuvenation treatments. You can check the deals they offer on this site.
PharmaResearch’s Strategic Realignment
PharmaResearch, a company specializing in regenerative medicine, has been in the news recently for its business split. Reports initially suggested that the company was spinning off its entire healthcare business, including skin rejuvenation injectables such as Rejuran and hyaluronic acid arthritis treatment Conjuran, into a 100 percent-owned subsidiary. However, PharmaResearch denied the reports, clarifying that while a separate subsidiary would be created to manage the non-aesthetic segment, the Rejuran business would remain central to its core operations.
The new subsidiary will distribute non-aesthetic products, such as Conjuran, Zadaxin, and the oral contraceptive Le-An. Meanwhile, PharmaResearch plans to focus on the aesthetics business, centered on Rejuran, to drive R&D and global market expansion. The company has shown impressive financial growth, with its medical device sector, including anti-aging injections and other beauty treatments, contributing significantly to revenue.
Hugel’s Leadership Changes and Market Strategy
Botulinum toxin maker Hugel is also undergoing a leadership change. After operating under co-CEOs Moon Hyoung-jin and Han Seon-ho, the latter recently announced his intention to step down six months before his term expires. Han’s potential departure was hinted at during the J.P. Morgan Healthcare Conference, where his name was absent from the executive team introductions.
Despite leadership shifts, Hugel reported record earnings, with its botulinum toxin product, Botulax, achieving significant sales growth. The company’s HA fillers, THE CHAEUM and BYRYZN, generated strong revenue, reinforcing Hugel’s position in the skincare and dermatology sectors. Hugel aims to enter the U.S. market this year with botox products, planning to secure a 10 percent market share within three years.
Classys and the Future of Korean Aesthetic Device Manufacturers
Classys, a leading manufacturer of energy-based dermatology devices, continues to face speculation that its largest shareholder, Bain Capital, may sell its stake in the company. Despite uncertainties, Classys reported strong financial performance, with revenues increasing by 34.8 percent year-on-year. The company is set to expand globally, launching new skin treatment devices in the U.S. and European markets.
With its focus on aesthetic rejuvenation treatments, Classys is positioned to lead the dermatology device sector. As Korean medical aesthetic supplies gain international demand, companies like Classys and PharmaResearch are driving innovation in anti-aging treatments, offering advanced solutions to beauty professionals worldwide.
The Korean medical aesthetics industry is rapidly evolving, with businesses balancing growth and structural changes. While challenges remain, the sector’s strong performance, coupled with advancements in skincare and beauty treatments, cements South Korea’s reputation as a global leader in aesthetic dermatology.
